An observational study in Breast Cancer and Breast Hypertrophy, sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Vastra Gotaland Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Breast Neoplasms by Vastra Gotaland Region — 13 open to participants now, 14 under way, 1 of them phase 3. Breast Neoplasms · Vastra Gotaland Region.
Among the 21 studies in Breast Neoplasms by Vastra Gotaland Region, this one is one of 5 that started in 2021, is one of 8 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 21 studies in Breast Neoplasms by Vastra Gotaland Region are open now, in 6 countries. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18–85
Vastra Gotaland Region · Sites in Sweden
Women only
Vastra Gotaland Region · Sites in Sweden
Ages 18+
Vastra Gotaland Region · Sites in Sweden
Ages 18+ · Women only
Vastra Gotaland Region · Sites in Sweden
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1
First in 2008; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 220 across the 13 interventional studies, 480 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
3 of the studies in Breast Neoplasms by Vastra Gotaland Region that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05363189Vastra Gotaland RegionOptimizing Postoperative Recovery After Breast Reconstruction With Autologous Tissue (BestDIEP) | 2026-12-31 |
| NCT04714463Vastra Gotaland RegionEffects of Expectations and Body Image in Breast Reconstruction | 2026-12-31 |
| NCT05222100Vastra Gotaland RegionEffect of Breast Implants om Mammography Screening | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Breast Neoplasms by Vastra Gotaland Region, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the project is to validate patient reported outcomes measures (PROMs) in reconstructive breast surgery. BREAST-Q will be evaluated for Swedish and Sweden.Hospital Anxiety and Depression Scale (HADS), EuroQol 5D (EQ5D), and SF-36 will be validated for reconstructive breast surgery. In addition, the complication classification system according to Clavien-Dindo will be validated for reconstructive breast surgery.
Women who will have or have had reconstructive breast surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who have had/have breast cancer and will have/have had a breast reconstruction.
Procedure: Breast reconstruction
Women who have had/will have a breast reduction due to breast hypertrophy.
Procedure: Breast reduction
Breast reconstruction after breast cancer.
Breast reduction due to breast hypertrophy.
Also known as: mammoplasty reduction
Validation and reliability of BREAST-Q for Sweden
Breast-Q measures breast related quality of life on a scale 1-100. A higher score indicates a higher quality of life.
Time frame: Pre-operatively
Validation and reliability of BREAST-Q for Sweden
Breast-Q measures breast related quality of life on a scale 1-100. A higher score indicates a higher quality of life.
Time frame: 5 years postoperatively
Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery
EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare. A total score between 0 and 1 is calculated. Zero equals death and 1 perfect health.
Time frame: Pre-operatively
Validation and reliability of EuroQol-5 dimensions, 3 levels for reconstructive breast surgery
EuroQol-5 dimensions-3 levels (EQ5D) is a generic instrument developed for health economic and clinical evaluation of healthcare. A total score between 0 and 1 is calculated. Zero equals death and 1 perfect health.
Time frame: 5 years postoperatively
Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery
The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).
Time frame: Pre-operatively
Validation and reliability of Hospital Anxiety and Depression scale (HADS) for Reconstructive breast surgery
The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21).
Time frame: 5 years postoperatively
Validation and reliability of RAND-36 for reconstructive breast surgery
It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales. Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale. A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.
Time frame: Pre-operatively
Validation and reliability of RAND-36 for reconstructive breast surgery
It comprises eight subdomains: physical functioning (10 items), role limitations caused by physical health problems (4 items), role limitations caused by emotional problems (3 items), social functioning (2 items), emotional well-being (5 items), energy/fatigue (4 items), pain (2 items), and general health perceptions (5 items) where patients score their health during the last four weeks on Likert scales. Every item score is transformed linearly to the per cent of total possible score (0-100) and then averaged by the values of the scale. A subscore is calculated for each domain and in addition two summary scores, physical and mental health, are calculated.
Time frame: 5 years postoperatively
Validation of Clavion-Dindo classification for reconstructive breast surgery
The Clavien-Dindo system is based on ranking the severity of the intervention required to treat a given complication, as follows: grade I includes deviations from the postoperative course without the need for pharmacological treatment or surgical/endoscopic/radiological intervention; grade II complications require pharmacological treatment, blood transfusion, or total parental nutrition; grade III complications require surgical/endoscopic/radiological intervention; grade IV includes life-threatening complications, including those involving the central nervous system, that require intensive care treatment; and grade V includes complications that result in death.
Time frame: 5 years postoperatively
Plan to share: No
Started Jun 2021 (actual). Primary completion is estimated for Dec 2027, 78 months after the start.
Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 78 months is above that.
Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.